Jude Dinges

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

Phadia AB develops, manufactures and markets blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. The company was founded in 2004 and is headquartered in Uppdala, Sweden.

Part of Thermo Fisher Scientific, Inc., Phadia US, Inc. engages in the research and development of blood testing products and instrumentation that aid in the diagnosis of allergy. The company is based in Portage, MI.

Shield Diagnostics Corp. develops advanced genotyping technologies for high throughput and high density testing. It offers beef and dairy cattle. The company was founded by Fred Turner and Sam Parlett and is headquartered in Santa Clara, CA.

AllerGenis LLC specializes in detecting and managing life-threatening food allergies. AllerGenis is based in Hatfield, PA, and the CEO of the joint venture company is Jim Garner. The company develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. AllerGenis owns and operates a CLIA-certified laboratory and is amassing the world's largest database of phenotypic patient data derived from epitope mapping, clinical history, and patient-reported outcomes. The company was founded in 2017 through a collaboration between Genisphere and Hugh Sampson MD of the Icahn School of Medicine at Mount Sinai.